Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Lyubov A. Kisakova"'
Autor:
Victoria R. Litvinova, Andrey P. Rudometov, Nadezhda B. Rudometova, Denis N. Kisakov, Mariya B. Borgoyakova, Lyubov A. Kisakova, Ekaterina V. Starostina, Anastasia A. Fando, Vladimir A. Yakovlev, Elena V. Tigeeva, Ksenia I. Ivanova, Andrei S. Gudymo, Tatiana N. Ilyicheva, Vasiliy Yu. Marchenko, Artemiy A. Sergeev, Alexander A. Ilyichev, Larisa I. Karpenko
Publikováno v:
Vaccines, Vol 12, Iss 5, p 538 (2024)
The development of a safe and effective vaccine against avian influenza A virus (AIV) H5N8 is relevant due to the widespread distribution of this virus in the bird population and the existing potential risk of human infection, which can lead to signi
Externí odkaz:
https://doaj.org/article/d93f756465fa44dca5a5e0190483f636
Autor:
Nadezhda B. Rudometova, Anastasia A. Fando, Lyubov A. Kisakova, Denis N. Kisakov, Mariya B. Borgoyakova, Victoria R. Litvinova, Vladimir A. Yakovlev, Elena V. Tigeeva, Danil I. Vahitov, Sergey V. Sharabrin, Dmitriy N. Shcherbakov, Veronika I. Evseenko, Ksenia I. Ivanova, Andrei S. Gudymo, Tatiana N. Ilyicheva, Vasiliy Yu. Marchenko, Alexander A. Ilyichev, Andrey P. Rudometov, Larisa I. Karpenko
Publikováno v:
Vaccines, Vol 12, Iss 2, p 143 (2024)
In this study, we characterized recombinant hemagglutinin (HA) of influenza A (H5N8) virus produced in Chinese hamster ovary cells (CHO-K1s). Immunochemical analysis showed that the recombinant hemagglutinin was recognized by the serum of ferrets inf
Externí odkaz:
https://doaj.org/article/1d51e53906da4e168b48bd8fd815c67c
Publikováno v:
Pharmaceutics, Vol 15, Iss 4, p 1106 (2023)
DNA and RNA vaccines (nucleic acid-based vaccines) are a promising platform for vaccine development. The first mRNA vaccines (Moderna and Pfizer/BioNTech) were approved in 2020, and a DNA vaccine (Zydus Cadila, India), in 2021. They display unique be
Externí odkaz:
https://doaj.org/article/1e544f950b5241e987cce27716113320
Autor:
Denis Nikolaevich Kisakov, Lyubov Alexandrovna Kisakova, Maria Borisovna Borgoyakova, Ekaterina Vladimirovna Starostina, Oleg Svyatoslavovich Taranov, Elena Konstantinovna Ivleva, Oleg Viktorovich Pyankov, Anna Vladimirovna Zaykovskaya, Dmitry Nikolaevich Shcherbakov, Andrey Pavlovich Rudometov, Nadezda Borisovna Rudometova, Natalia Vyacheslavovna Volkova, Vadim Nikolaevich Gureev, Alexander Alexeyevich Ilyichev, Larisa Ivanovna Karpenko
Publikováno v:
Pharmaceutics, Vol 14, Iss 11, p 2259 (2022)
Vaccination against SARS-CoV-2 and other viral infections requires safe, effective, and inexpensive vaccines that can be rapidly developed. DNA vaccines are candidates that meet these criteria, but one of their drawbacks is their relatively weak immu
Externí odkaz:
https://doaj.org/article/03aa0fd082b54641918c785339d4c2c4